Obesity Treatment

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

AT A GLANCE DaVita Inc. issued a statement in response to Novo Nordisk in relation ‘…to its FLOW study that sought to demonstrate that Ozempic delays progression of chronic kidney disease (CKD) and lowers the risk of kidney and cardiovascular mortality.’ Retatrutide, an Eil Lilly drug yet to be approved by the FDA, boasting ‘…Phase 2 trial results […]

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials. Read More »

Insurers “clamping down” on costly GLP-1s; BMI challenged; teens and obesity treatment; and skyrocketing Type 2 diabetes in India.

Hope everyone is quite well this week. For those dads out there, warm wishes for a very happy Father’s Day! And I’d also like to note, with deep respect, that tomorrow is Junteenth and a holiday for twenty30 health, as we commemorate the emancipation of enslaved Black Americans on what many view as America’s second Independence

Insurers “clamping down” on costly GLP-1s; BMI challenged; teens and obesity treatment; and skyrocketing Type 2 diabetes in India. Read More »

Scroll to Top
Skip to content